Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study
- PMID: 29296703
- PMCID: PMC5728349
- DOI: 10.1182/bloodadvances.2016002675
Survival outcomes in the very elderly with DLBCL prior to and after the introduction of rituximab: a US population-based study
Conflict of interest statement
Conflict-of-interest disclosure: The authors declare no competing financial interests.
Figures
Comment in
-
Treatment and relative survival in very elderly patients with DLBCL in The Netherlands: a population-based study, 1989 to 2015.Blood Adv. 2017 Sep 22;1(21):1839-1841. doi: 10.1182/bloodadvances.2017011031. eCollection 2017 Sep 26. Blood Adv. 2017. PMID: 29297513 Free PMC article. No abstract available.
References
-
- He W, Goodkind D, Kowal P. An Aging World: 2015: international population reports. Washington, DC: U.S. Government Publishing Office; 2016
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29. - PubMed
-
- Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359(6):613-626. - PubMed
-
- Coiffier B, Lepage E, Briere J, et al. . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources